| Q39407209 | A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine |
| Q77601616 | A practical guide to the management and prevention of migraine |
| Q28192002 | Advances in pharmacological treatment of migraine |
| Q39181878 | Age But Not Sex Is Associated With Efficacy and Adverse Events Following Administration of Intravenous Migraine Medication: An Analysis of a Clinical Trial Database |
| Q37897224 | Almotriptan for menstrually related migraine |
| Q39404886 | Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial |
| Q34341673 | Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. |
| Q37610996 | Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting |
| Q37695402 | Current practice and future directions in the prevention and acute management of migraine |
| Q31119065 | Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies |
| Q39361381 | Efficacy of oral naratriptan in the treatment of menstrually related migraine |
| Q37939992 | Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea |
| Q74577202 | Headache Recurrence and Treatment |
| Q34634351 | Headache recurrence as a criterion for assessing efficacy of triptans: a perspective |
| Q43989436 | Is there a preferred triptan? |
| Q28376494 | Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence |
| Q50047547 | Menstrual migraine: a review of current and developing pharmacotherapies for women |
| Q35759346 | Menstrual migraine: a review of prophylactic therapies |
| Q36941893 | Menstrual migraine: clinical and therapeutical aspects |
| Q35091964 | Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans |
| Q43050704 | Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial |
| Q34647375 | Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials |
| Q48499035 | Pain characteristics of the acute migraine attack |
| Q39461967 | Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. |
| Q46783017 | Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database |
| Q44378432 | Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University |
| Q34623397 | Prevention and Treatment of Menstrual Migraine |
| Q41371800 | Serotonin 1D (5-HT1D) agonists and other agents in acute migraine |
| Q30241432 | Sex differences in the epidemiology, clinical features, and pathophysiology of migraine |
| Q37883445 | Sex-related differences in epidemiological and clinic-based headache studies. |
| Q39447453 | Sumatriptan. An updated review of its use in migraine |
| Q53215140 | The International Classification of Headache Disorders: accurate diagnosis of orofacial pain? |
| Q43725563 | The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial |
| Q33952000 | The pharmacology of headache |
| Q35048015 | Tolerability of the triptans: clinical implications |
| Q33987376 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan |
| Q34154647 | Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials |
| Q30584718 | Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data |
| Q36260684 | What can be learned from the history of recurrence in migraine? A comment |
| Q44171180 | Which triptan is best? Rating of triptans in migraine treatment |
| Q36367884 | Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy |
| Q79907241 | [Clinical use of triptans in the management of migraine] |